Northern Trust Corp Tcr2 Therapeutics Inc. Transaction History

Northern Trust Corp

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.0 - $1.62 $7,441 - $12,054	7,441 Added 8.6%	93,933 $140,000
Q4 2022 Feb 13, 2023	SELL	$0.83 - $1.44 $2,756 - $4,782	-3,321 Reduced 3.7%	86,492 $86,000
Q3 2022 Nov 14, 2022	BUY	$1.86 - $3.75 $7,209 - $14,535	3,876 Added 4.51%	89,813 $161,000
Q2 2022 Aug 12, 2022	SELL	$2.11 - $2.94 $424,772 - $591,863	-201,314 Reduced 70.08%	85,937 $249,000
Q1 2022 May 13, 2022	SELL	$2.4 - $4.71 $64,608 - $126,793	-26,920 Reduced 8.57%	287,251 $793,000
Q4 2021 Feb 08, 2022	SELL	$4.58 - $8.34 $46,436 - $84,559	-10,139 Reduced 3.13%	314,171 $1.46 Million
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $57,839 - $125,752	-6,853 Reduced 2.07%	324,310 $2.76 Million
Q2 2021 Aug 13, 2021	BUY	$16.41 - $24.71 $28,520 - $42,945	1,738 Added 0.53%	331,163 $5.44 Million
Q1 2021 May 12, 2021	SELL	$20.38 - $34.07 $141,946 - $237,297	-6,965 Reduced 2.07%	329,425 $7.27 Million
Q4 2020 Feb 11, 2021	SELL	$19.0 - $32.63 $131,043 - $225,049	-6,897 Reduced 2.01%	336,390 $10.4 Million
Q3 2020 Nov 16, 2020	BUY	$13.1 - $20.69 $1.16 Million - $1.83 Million	88,283 Added 34.62%	343,287 $6.98 Million
Q2 2020 Aug 14, 2020	BUY	$6.51 - $16.85 $658,493 - $1.7 Million	101,151 Added 65.75%	255,004 $3.92 Million
Q1 2020 May 14, 2020	BUY	$6.01 - $16.01 $37,694 - $100,414	6,272 Added 4.25%	153,853 $1.19 Million
Q4 2019 Feb 14, 2020	BUY	$12.17 - $17.88 $90,179 - $132,490	7,410 Added 5.29%	147,581 $2.11 Million
Q3 2019 Nov 13, 2019	BUY	$10.15 - $19.53 $1.42 Million - $2.74 Million	140,171 New	140,171 $2.11 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.